Key Metrics
12.41
Heat Index-
Impact LevelMedium
-
Scope LevelGlobal
-
Last Update2025-11-24
Key Impacts
Positive Impacts (3)
Eli Lilly and Company
Biogen Inc.
Eisai Co., Ltd.
Negative Impacts (4)
Novo Nordisk A/S
OMX Copenhagen 25 Index (OMXC25)
EURO STOXX 600 Healthcare Index
Alzheimer’s Drug Development Biotech Sector
Total impacts: 8 |
Positive: 3 |
Negative: 4
Event Overview
Pharmaceutical company stock experiences a significant drop following the release of clinical trial results. The drug, aimed at slowing Alzheimer's disease, did not meet the expected efficacy, leading to market disappointment and financial impact.
Collect Records
Novo Nordisk's Stock Falls Over 10% After Alzheimer's Drug Trial Results
2025-11-24 19:26
The stock price of Novo Nordisk fell by more than 10% in pre-market trading. This decline was due to the results of the Evoke Phase III clinical trial, which showed that the drug did not significantly slow the progression of Alzheimer's disease in a statistically significant manner.
Total records: 1